AMR Dx Global
Surveillance
- Till Bachmann, University of Edinburgh, United Kingdom (Coordinator)
- Frank Bier, Fraunhofer Institute for Cell Therapy and Immunology, Germany (Observer)
- Gerd Luedke, Curetis GmbH, Germany (Observer)
- Guido Werner, Robert Koch Institute, Germany (Observer)
- Gunnar Skov Simonsen, University Hospital of North Norway, Norway (Observer)
- Gyorgy Abel, Lahey Hospital & Medical Center and Harvard Medical School, USA (Observer)
- Harald Peter, Fraunhofer Institute for Cell Therapy and Immunology, Germany (Observer)
- Herman Goossens, University of Antwerp, Belgium (Observer)
- Jacob Moran-Gilad, Ben-Gurion University, Israel (Observer)
- Jane Carter, Amref International University, Kenya (Observer)
- Javier R. Ambrosio, National Autonomous University of Mexico (UNAM), Mexico (Observer)
- Alex van Belkum, BioMérieux, France (Observer)
- Jean-François de Lavison, Ahimsa Fund, France (Observer)
- John P. Hays, Erasmus MC University Medical Center, Netherlands (Observer)
- Jordi Vila, Barcelona Institute for Global Health (ISGlobal), Spain (Observer)
- Karsten Becker, Friedrich Loeffler-Institute of Medical Microbiology, Germany (Observer)
- Konstantinos Mitsakakis, Hahn-Schickard, University of Freiburg, Germany (Observer)
- Neil Woodford, Public Health England, United Kingdom (Observer)
- Ossama S. Rasslan, Ain Shams University, Egypt (Observer)
- Pieter Moons, ND4ID (New Diagnostics for Infectious Diseases), Belgium (Observer)
- Ramanan Laxminarayan, Center for Disease Dynamics, Economics & Policy, India (Observer)
- Ravi Krishnan Elangovan, Indian Institute of Technology, India (Observer)
- Alison Prendiville, University of the Arts London, United Kingdom (Observer)
- Richard Stabler, Liverpool School of Tropical Medicine, United Kingdom (Observer)
- Rosanna Peeling, Liverpool School of Tropical Medicine, United Kingdom (Observer)
- Saturnino Luz, University of Edinburgh, United Kingdom (Observer)
- Shaheen Mehtar, Infection Control Africa Network (ICAN), South Africa (Observer)
- Sören Schubert, Max von Pettenkofer Institute Munich, Germany (Observer)
- Stefan Schwarz, Freie Universität Berlin, Germany (Observer)
- Stephan Harbarth, University Hospitals Geneva, Switzerland (Observer)
- Susan M. Poutanen, University of Toronto, Canada (Observer)
- Taslimarif Saiyed, Centre for Cellular and Molecular Platforms, India (Observer)
- Mark Woolhouse, University of Edinburgh, United Kingdom (Observer)
- Aman Russom, KTH Royal Institute of Technology, Sweden (Observer)
- Thomas A. Wichelhaus, Institute of Medical Microbiology and Infection Control, Germany (Observer)
- Valentina Di Gregori, European Public Health Association and Gvm Care and Research, Italy (Observer)
- Terri Roberts, MSF, Switzerland (Observer)
- Amani Ali El- Kholy, University of Cairo, Egypt (Observer)
- Cassandra Kelly-Cirino, Foundation for Innovative New Diagnostics (FIND), Switzerland (Observer)
- Daniel Berman, Longitude Prize, Nesta, United Kingdom (Observer)
- Evelina Tacconelli, University Hospital Tübingen, Germany (Observer)
- Francis Moussy, World Health Organization (WHO), Switzerland (Observer)
Diagnostics is one of the most important tools to tackle the global threat of antimicrobial resistance (AMR). AMR Dx Global is an international network with partners in 15 countries funded by the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) as part of the emerging Virtual Research Institute (VRI) and coordinated by University of Edinburgh. The network addresses the needs for teaching and training in relation to AMR diagnostics from a One Health perspective. The network conducted stakeholder mapping, content and delivery roadmapping as well as a demand survey for teaching and training on AMR diagnostics which includes for any type of diagnostics or test to provide information in the wider context of antibiotics, antibacterial resistance or infection such as tests for bacteria, antibiotic resistance genes, antibiotic susceptibilities, infection biomarkers, or antibiotic residues. The AMR Dx provides input into the formation of the JPIAMR VRI and recommends a strong presence of AMR diagnostics in the emerging platform.